Lisa A. Carey spends much of her time researching Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. The various areas that Lisa A. Carey examines in her Breast cancer study include Gene expression profiling, Epidermal growth factor receptor and Pathology. Her work on Internal medicine is being expanded to include thematically relevant topics such as MEDLINE.
Her studies in Oncology integrate themes in fields like Neoadjuvant therapy, Chemotherapy, Trastuzumab, Metastatic breast cancer and Metastasis. Her Cancer research is multidisciplinary, incorporating elements of Guideline, Gynecology and Psychiatry. Her biological study spans a wide range of topics, including Neoplasm, Microarray, Disseminated cancer and Drug resistance.
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Her Breast cancer study incorporates themes from Clinical trial, Disease and Gynecology. Her Internal medicine study frequently draws connections to adjacent fields such as Surgery.
Her work carried out in the field of Oncology brings together such families of science as Phases of clinical research, Paclitaxel, Pathology, Lapatinib and Bevacizumab. Her Cancer research incorporates elements of Cancer research and Confidence interval. Her research integrates issues of Adjuvant and Anthracycline in her study of Chemotherapy.
Her main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. Lisa A. Carey is interested in Estrogen receptor, which is a field of Breast cancer. The concepts of her Oncology study are interwoven with issues in Previously treated, Neoadjuvant therapy, Receptor, Biomarker and Triple-negative breast cancer.
Her Neoadjuvant therapy research incorporates themes from Odds ratio, Meta-analysis and Genomic Biomarker. Lisa A. Carey has included themes like Mutation and Gerontology in her Cancer study. Lisa A. Carey combines subjects such as Endocrine therapy, Discontinuation and Anthracycline with her study of Chemotherapy.
Lisa A. Carey mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Estrogen receptor. Her Internal medicine study is mostly concerned with Receptor, Triple-negative breast cancer, Previously treated, Trastuzumab and Capecitabine. She has researched Trastuzumab in several fields, including Metastatic breast cancer and Randomized controlled trial.
Her Oncology study frequently draws connections to other fields, such as HER2 Positive Breast Cancer. Her Breast cancer research is multidisciplinary, relying on both Biomarker, Guideline and Clinical trial. Her studies deal with areas such as Immunohistochemistry, HER2 negative, Endocrine system, Stage ii and Locally advanced as well as Estrogen receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A. Carey;Charles M. Perou;Chad A. Livasy;Lynn G. Dressler.
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey;E. Claire Dees;Lynda Sawyer;Lisa Gatti.
Clinical Cancer Research (2007)
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu;Cheng Fan;Daniel S Oh;JS Marron.
BMC Genomics (2006)
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
James D. Brenton;Lisa A. Carey;Ahmed Ashour Ahmed;Carlos Caldas.
Journal of Clinical Oncology (2005)
Epidemiology of basal-like breast cancer
Robert C. Millikan;Beth Newman;Chiu Kit Tse;Patricia G. Moorman.
Breast Cancer Research and Treatment (2008)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey;Eric Winer;Giuseppe Viale;David Cameron.
Nature Reviews Clinical Oncology (2010)
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh.
Journal of Clinical Oncology (2015)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)
Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals.
Annette Flanagin;Lisa A. Carey;Phil B. Fontanarosa;Stephanie G. Phillips.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: